Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc a biopharmaceutical company focuses on discovering developing and commercializing novel therapeutics based on ribonucleic acid interference The companys pipeline of investigational RNAi therapeutics focuses on genetic medicines cardiometabolic diseases hepatic infectious diseases and central nervous system CNSocular diseases Its marketed products include ONPATTRO patisiran a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretinmediated amyloidosis in adults GIVLAARI for the treatment of adults with acute hepatic porphyria AHP and OXLUMO lumasiran for the treatment of primary hyperoxaluria type 1 PH1 In addition the company is developing givosiran for the treatment of adolescent patients with AHP patisiran for the treatment of transthyretin amyloidosis or ATTR amyloidosis with cardiomyopathy cemdisiran to treat complementmediated diseases ALNAAT02 for the treatment of AAT deficiencyassociated liver disease ALNHBV02 to treat chronic HBV infection Zilebesiran to treat hypertension and ALNHSD to treat NASH Further it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders Inclisiran to treat hypercholesterolemia lumasiran for the treatment of advanced PH1 and recurrent renal stones and vutrisiran for the treatment of ATTR amyloidosis which is in phase 3 clinical trial Alnylam Pharmaceuticals Inc has strategic collaborations with Regeneron Pharmaceuticals Inc to discover develop and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS and Sanofi Genzyme to discover develop and commercialize RNAi therapeutics It also has license and collaboration agreements with Novartis AG Vir Biotechnology Inc Dicerna Pharmaceuticals Inc Ionis Pharmaceuticals Inc and PeptiDream Inc The company was founded in 2002 and is headquartered in Cambridge Massachusetts